Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAGE-718

Small molecule · developed by Supernus Pharmaceuticals

Phase 3 Most advanced trial (none active)
SUPN Developer
1 Registered trials

What is SAGE-718?

SAGE-718 is an oral softgel lipid capsule formulation studied in Huntington's Disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Supernus Pharmaceuticals, Inc. (SUPN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8ENS5K3JW8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05655520 Phase 3 Huntington's Disease Terminated SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Huntington's Disease

More from Supernus Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.

Follow SUPN, the company behind SAGE-718

See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SUPN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.